AbbVie filed an 8-K on April 29, 2026, announcing its financial results for the first quarter of 2026, which ended March 31, 2026.

Teva Pharmaceutical Industries Ltd. announced its first quarter 2026 financial results and a definitive agreement to acquire Emalex Biosciences in an 8-K filing on April 29, 2026.

Ionis Pharmaceuticals, Inc. (IONS) filed an 8-K on April 29, 2026, announcing its financial results for the quarter ended March 31, 2026.

Regeneron Pharmaceuticals filed an 8-K on April 29, 2026, announcing its financial and operating results for the first quarter of 2026, which ended March 31, 2026.

Biogen Inc. (BIIB) filed an 8-K on April 29, 2026, announcing its financial results for the first quarter of 2026, which ended on March 31, 2026. The filing includes a press release (Exhibit 99.

BioMarin Pharmaceutical Inc. announced the completion of its acquisition of Amicus Therapeutics, Inc. The merger was finalized on April 27, 2026, with Amicus becoming a wholly-owned subsidiary of BioM...

Perrigo Company plc announced a change to its reporting segments, shifting from a geographic structure to a product category-based structure, effective Q1 2026.

Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD), a rare and often fatal neurological condition.

Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase. The company announced a 3.

BeOne Medicines Ltd. (BGNE) filed an 8-K on April 14, 2026, pertaining to its 2025 Annual Report filed with the Shanghai Stock Exchange's STAR Market.